JPRN-UMIN000012098已完成2 期
Phase II Study of Alternate-day Administration of S-1 plus Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer - Phase II Study of Alternate-day Administration of S-1 plus Carboplatin in Elderly Patients with Non-small Cell Lung Cancer
Tokushukai Group Oncology Project0 个研究点目标入组 45 人开始时间: 2013年10月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Past history of severe drug hypersensitivity 2) Severe bone marrow suppression, renal dysfunction, or liver dysfunction 3) Treatment history of S-1, except for the cases in which S-1 had been administered as adjuvant chemotherapy and recurrence was observed more than 1 year after thoracic surgery 4) Active double cancer within 5 years of disease-free interval, except for curable lesions like carcinoma in situ and mucosal cancer 5) Severe complication such as ileus, interstitial pneumonia, uncontrolled diabetes, heart failure, renal dysfunction, liver dysfunction, active digestive ulcer, and acute myocardial infarction or angina pectoris within six months 6) Diarrhea graded 2 or more 7) Active infectious disease in need of systemic administration of antibiotics 8) Uncontrolled pleural effusion, ascites, and pericardial effusion which needs drainage 9) Uncontrolled symptomatic brain metastasis 10) Systemic administration of steroid 11) Patients with psychiatric disease or symptoms, who seem to have difficulty in participating in the study 12) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
已完成
2 期
Phase II Study of Alternate-day Administration of S-1 plus Carboplatin in Elderly Patients with Previously Treated Non-small Cell Lung CancerJPRN-UMIN000010989Tokushukai Group Oncology Project32
已完成
2 期
Phase II study of alternate-day administrations of S-1 as 2nd-line treatment in patients with metastatic and locally advanced pancreatic cancerMetastatic or locally advanced pancreatic cancerJPRN-UMIN000003454Pancreatic Cancer Treatment Research Group45
已完成
1 期
A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.colorectal cancerJPRN-UMIN000016094Aichi Cancer Center Hospital16
已完成
2 期
Phase II study of alternate-day administrations of S-1 as 1st-line treatment in patients with metastatic and locally advanced pancreatic cancerMetastatic or locally advanced pancreatic cancerJPRN-UMIN000003453Pancreatic Cancer Treatment Research Group45
已完成
2 期
A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.Colorectal cancerJPRN-UMIN000020439Aichi Cancer Center Hospital25
